Molecular diagnostics have emerged as the cornerstone of MPN diagnosis, with their ability to not only exclude a BCR::ABL1 fusion gene but also to differentiate MPN from reactive haematological changes and to determine disease progression. Here, ABL1 is linked to myeloproliferative disorder.